Navigation Links
Inside Job: Medical Negligence Lawyers at Console & Hollawell Comment on Risks to Dialysis Patients and Impending Legal Action Over Fresenius Controversy
Date:2/11/2013

Marlton, NJ (PRWEB) February 11, 2013

One in 10 adults in the United States has some form of chronic kidney disease, according to the Centers for Disease Control and Prevention. Hundreds of thousands are on dialysis, dependent on drugs manufactured by companies like Fresenius Medical Care to remove toxins from their blood. The procedure is time consuming and dangerous enough without the medications themselves doing more harm than good. A report made public just last year shows Fresenius may have withheld critical information from patients and doctors about the dangers of its dialysis meds, particularly GranuFlo and NaturaLyte, stated in an article from the New York Times. The potential for a massive number of patients to suffer life-threatening injuries has Philadelphia attorney Richard P. Console Jr. calling for greater accountability.

“To sit on the knowledge that your products could cause potentially lethal complications for patients is shocking behavior,” said Console. “It’s not as though it’s an independent report from an outside source. This is the company’s own medical office saying there’s a high risk of adverse, deadly events associated with their dialysis medications. There could be thousands of victims out there in real need of help.”

Fresenius Medical Care treats an estimated 400,000 dialysis patients in the United States, according to the New York Times. The company is also the leading supplier of dialysis machines and one-use dialysis products. Clinics around the country, including the company’s own facilities, use them every day. Fresenius’ internal memo, originally circulated in 2011, reportedly revealed a sharp increase in the number of sudden cardiac arrests in patients using GranuFlo.

The memo claimed 941 patients suffered cardiac arrest while inside Fresenius clinics in 2010, which the company’s medical team attributed to high levels of bicarbonate in their blood. Acetate ingredients in GranuFlo and other dialysis products made by Fresenius reportedly led to the spikes in bicarbonate, which caused a six-fold increase in the risk of cardiac arrest. Console, whose law firm has been practicing in the Philadelphia area since 1994, believes these events were preventable.

“The company had an opportunity to get out in front of this issue, warn patients, and inform doctors to alter dialysis treatment plans,” Console said. “From all the information available, it doesn’t appear that was done, and people may have suffered significantly because of that failure. Victims deserve compensation for the pain and serious injuries they’ve endured. Losing a loved one to a preventable condition is unacceptable, especially when there’s evidence to suggest the company knew the problem existed long before they did anything to stop it.”

On the heels of an investigation by the U.S. Food and Drug Administration (FDA) into Fresenius’ delay in informing the public about known risks of its products, the company issued a Class I recall of GranuFlo and NaturaLyte in June 2012. A Class I recall is the most serious form of drug recall, used only when a product presents a probable risk of harm to patients.

Richard P. Console Jr. is the managing partner of Console & Hollawell P.C., a personal injury law firm that has helped more than 5,000 victims in Philadelphia, including those affected by defective medical products, obtain the compensation they deserve.    

http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0

http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/

Read the full story at http://www.prweb.com/releases/2013/2/prweb10405530.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Inside a machine for turning coffee into science
2. New Novel Looks at British NHS from the Inside
3. Fitness Celebrity and one of Canada’s Inside Fitness Hot and Fit Women of 2012, Nancy Di Nino, brings her Media Personality to host the Hot & Fit Release Party
4. Corporate Whistle Blower Center Now Urges Physicians Medical Device and Drug Industry Insiders To Step Up-If They Have Proof Of Serious Wrongdoing or Overbilling
5. Corporate Whistle Blower Center Now Urges Physicians, Medical Device or Drug Insiders With Proof A Company Knowingly Sold A Bad Product to Become a Whistleblower
6. Prime Medical Associates’ Sleep Lab Featured in Insider Magazine
7. Skin Authority Creates One-of-a-Kind Solution for the One Billion People Worldwide Who are Vitamin D Deficient -- Groundbreaking Launch of "Inside Out" System
8. Corporate Whistle Blower Center Now Urges Medical Industry Insiders to Blow the Whistle if They Can Prove a Medical Product was Defective and Their Company Sold it Anyway
9. New MRI technology to provide even better images of the inside of the human body
10. Smart scaffolding aims to rebuild tissue from the inside
11. Parents skin cancer concern doesnt keep kids inside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: